One of the at-home ketamine industry’s biggest boosters has turned bearish, calling for caution among patients and providers and withdrawing his endorsement of the practice.
“After being at the forefront of at-home ketamine treatment, recent findings, like the case study of unintentional overdose via telehealth have led me to reevaluate,” said Juan Pablo Cappello, who founded at-home ketamine company Nue Life Health.
Here, we take a closer look at the case study that changed Cappello’s mind as well as broader concerns around at-home ketamine operators, and we speak with Cappello himself.
This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
